Transcode reports durable disease control and no DLTs with TTX-MC138 in Phase 1a update

Transcode reported continued disease stabilization and extended treatment duration with TTX-MC138 in its Phase 1a trial.Key Highlights:Original SEC Filing: Transcode Therapeutics, Inc. [ RNAZ ] - 8-K - Sep. 28, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying impor…